00:06 , Dec 20, 2018 |  BC Extra  |  Company News

Management tracks: Prometic, Synlogic

Prometic Life Sciences Inc. (TSX:PLI; OTCQX:PFSCF) board member and CEO Pierre Laurin stepped down to pursue other opportunities. Chairman Simon Best was named interim CEO while the fibrosis and orphan disease company searches for a...
21:06 , Apr 6, 2018 |  BioCentury  |  Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
22:49 , Apr 3, 2018 |  BC Extra  |  Company News

Management tracks: Abeona, Dermavant, Assembly

Gene therapy play Abeona Therapeutics Inc. (NASDAQ:ABEO) said President and CEO Timothy Miller will transition to president and CSO. He is succeeded as CEO by Carsten Thiel, who was EVP and chief commercial officer at...
20:51 , Mar 2, 2018 |  BC Week In Review  |  Clinical News

Prometic discontinues Phase II of PBI-4050 to treat cystic fibrosis related diabetes

Prometic Life Sciences Inc. (TSX:PLI; OTCQX:PFSCF) said it will discontinue a Phase II trial of PBI-4050 to treat cystic fibrosis related diabetes due to slow patient enrollment. The company said most CF patients were ineligible...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
23:24 , Nov 30, 2017 |  BC Week In Review  |  Clinical News

Prometic reports Phase II data for PBI-4050 in Alstrom syndrome

In September, Prometic Life Sciences Inc. (TSX:PLI; OTCQX:PFSCF) reported data from 8 patients with Alstrom syndrome in a Phase II trial showing that oral PBI-4050 decreased liver stiffness, as measured by FibroScan, to a median...
20:54 , Oct 13, 2017 |  BC Extra  |  Company News

Priority Review for Prometic’s plasminogen therapy

Prometic Life Sciences Inc. (TSX:PLI; OTCQX:PFSCF) said FDA accepted and granted Priority Review to a BLA for Ryplazim human plasma-derived plasminogen to treat plasminogen deficiency. Its PDUFA date is April 14, 2018. The human plasma-derived...
23:45 , Sep 27, 2017 |  BC Extra  |  Company News

Management tracks: Gilead, Tango, Rubius, Bicycle

Gilead Sciences Inc. (NASDAQ:GILD) said COO Kevin Young will retire, effective early 2018. Young returned to Gilead as COO in May 2016 after brief retirement during which he acted as an advisor. He was Gilead's...
15:16 , Sep 1, 2017 |  BC Week In Review  |  Clinical News

Prometic's Ryplazim gets rare pediatric disease designation

Prometic Life Sciences Inc. (TSX:PLI; OTCQX:PFSCF) said FDA granted rare pediatric disease designation to Ryplazim to treat congenital plasminogen deficiency. The human plasma-derived plasminogen also has Orphan Drug and Fast Track designations from FDA. Last...
23:26 , Aug 29, 2017 |  BC Extra  |  Company News

Prometic gains on rare pediatric disease designation

Prometic Life Sciences Inc. (TSX:PLI; OTCQX:PFSCF) said FDA granted rare pediatric disease designation to Ryplazym to treat congenital plasminogen deficiency. The company gained C$0.30 (25%) to C$1.50 in Toronto on Tuesday, and $0.22 (22%) to...